As it continues exploring options to extend its cash runway, which could include a merger or sale, Karyopharm Therapeutics is cutting about 20% of its workforce, according to a July 11 SEC filing. The Newton, Massachusetts–based commercial-stage pharma did not specify which locations the layoffs affect.
